Doctorate from the University of Wageningen. MBA with distinction from the University of Nyenrode and the University of Rochester, NY. Doctorandus degree in Molecular Biology, Genetics and Biochemistry from the University of Nijmegen, The Netherlands. Co-founder of NextWaveBio. Led the development of Flublok®, the only FDA approved recombinant influenza vaccine while serving as President and Chief Executive Officer of Protein Sciences Corporation.
Doctorate from University of Sydney, Department of Infectious Diseases. Bachelor of Science University of New South Wales, Department of Micro biology and Immunology. Director of Immunisation Coalition and Director/Founder of Environmental Pathogens. Former Director of Immunobiology and WHO ERL at the TGA, and former WHO Advisor and Consultant.
Doctoral degree in Molecular and Cellular Physiology from Stanford University School of Medicine. Holds more than 47 issued US/EU/Japan patents and 4 discoveries in clinical trials. Over 30 years of pharmaceutical leadership experience including Genentech, Repligen, ZymoGenetics, Immunex, and Amgen.
Mary Holland is a former Research Scholar and Director of the Graduate Lawyering Program at NYU School of Law. She has written several law review articles and blog posts on vaccine law and policy and is the co-author and co-editor of the books “Vaccine Epidemic” and “HPV Vaccine on Trial: Seeking Justice for a Generation Betrayed.” She is chair of the advisory board of Health Choice, legal counsel to and board member of Children’s Health Defense. Educated at Harvard and Columbia Universities, Holland has worked in international public and private law.